Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

Shares of Intellia Therapeutics NTLA have witnessed a sharp decline in the past month, primarily due to a regulatory setback faced with one of its lead in vivo candidates, nex-z (formerly known as ...

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...

Stocks in the news, IPO offerings, IPO listing watchlist, corporate actions and more: your complete guide for the today!

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Shares of gene-editing company Intellia Therapeutics continue to struggle under significant pressure. This follows the U.S. Food and Drug Administration's (FDA) decision to halt the firm's most ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 11.76% on an annualized basis producing an average annual return of 23.85%. Currently, Regeneron ...

Broadcom stock fell despite record AI revenue growth as investors weigh margin pressure, valuation risks and future demand.

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...